Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial

The Lancet

Volumn 378, Issue 9807, 2011, Pages 1940-1948

  Stefanini, Giulio G ^a   Kalesan, Bindu ^a,b   Serruys, Patrick W ^c   Heg, Dik ^b   Buszman, Pawel ^d   Linke, Axel ^e   Ischinger, Thomas ^f   Klauss, Volker ^g   Eberli, Franz ^h   Wijns, William ⁱ   Morice, Marie Claude ^j   Di Mario, Carlo ^k   Corti, Roberto ^l   Antoni, Diethmar ^m   Sohn, Hae Y ^g   Eerdmans, Pedro ⁿ   Van Es, Gerrit Anne ^o   Meier, Bernhard ^a   Windecker, Stephan ^a   Jüni, Peter ^b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d MEDICAL UNIVERSITY OF SILESIA   (Poland)

^e UNIVERSITY OF LEIPZIG HEART CENTER   (Germany)

^f Kardiologie im Zentrum   (Germany)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^h TRIEMLI HOSPITAL   (Switzerland)

ⁱ OLV HOSPITAL   (Belgium)

^j Institut Cardiovasculaire   (France)

^k ROYAL BROMPTON HOSPITAL   (United Kingdom)

^l UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^m KLINIKUM BOGENHAUSEN   (Germany)

ⁿ Biosensors International Group Ltd   (Switzerland)

^o CARDIALYSIS   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIODEGRADABLE POLYMER; DURABLE POLYMER; POLYMER; RAPAMYCIN; UMIROLIMUS; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CORONARY ARTERY DISEASE; DRUG ELUTING STENT; DRUG SAFETY; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; STENT THROMBOSIS; TARGET VESSEL REVASCULARISATION;

EID: 82755195016     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61672-3     Document Type: Article

References (40)

1. C Stettler, S Wandel, S Allemann et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis Lancet 370 2007 937 948 (Pubitemid 47393576)
2. P Wenaweser, J Daemen, M Zwahlen et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice: 4-year results from a large 2-institutional cohort study J Am Coll Cardiol 52 2008 1134 1140
3. A Kastrati, J Mehilli, J Pache et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents N Engl J Med 356 2007 1030 1039 (Pubitemid 46376803)
4. C Spaulding, J Daemen, E Boersma, DE Cutlip, PW Serruys A pooled analysis of data comparing sirolimus-eluting stents witxare-metal stents N Engl J Med 356 2007 989 997 (Pubitemid 46376799)
5. GW Stone, JW Moses, SG Ellis et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents N Engl J Med 356 2007 998 1008 (Pubitemid 46376800)
6. AJ Carter, M Aggarwal, GA Kopia et al. Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model Cardiovasc Res 63 2004 617 624 (Pubitemid 39078675)
7. G Nakazawa, AV Finn, M Joner et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study Circulation 118 2008 1138 1145
8. AV Finn, G Nakazawa, M Joner et al. Vascular responses to drug eluting stents: importance of delayed healing Arterioscler Thromb Vasc Biol 27 2007 1500 1510 (Pubitemid 46986103)
9. S Cook, E Ladich, G Nakazawa et al. Correlation of intravascular ultrasound findings with histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent thrombosis Circulation 120 2009 391 399
10. M Joner, AV Finn, A Farb et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk J Am Coll Cardiol 48 2006 193 202 (Pubitemid 43929240)
11. GJ Wilson, G Nakazawa, RS Schwartz et al. Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries Circulation 120 2009 141 149
12. S Windecker, PW Serruys, S Wandel et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial Lancet 372 2008 1163 1173
13. P Barlis, E Regar, PW Serruys et al. An optical coherence tomography study of a biodegradable vs durable polymer-coated limus-eluting stent: a LEADERS trial sub-study Eur Heart J 31 2010 165 176
14. R Prineas, RHB Crow The Minnesota code manual of electrocardiographic findings 1982 John Wright-PSG Littleton, MA
15. DE Cutlip, S Windecker, R Mehran et al. Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351 (Pubitemid 46685903)
16. A Dibra, A Kastrati, F Alfonso et al. Effectiveness of drug-eluting stents in patients with bare-metal in-stent restenosis. Meta-analysis of randomized trials J Am Coll Cardiol 49 2007 616 623 (Pubitemid 46177448)
17. HK Win, AE Caldera, K Maresh et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents JAMA 297 2007 2001 2009 (Pubitemid 46740352)
18. N Beohar, CJ Davidson, KE Kip et al. Outcomes and complications associated with off-label and untested use of drug-eluting stents JAMA 297 2007 1992 2000 (Pubitemid 46740351)
19. OC Marroquin, F Selzer, SR Mulukutla et al. A comparison of bare-metal and drug-eluting stents for off-label indications N Engl J Med 358 2008 342 352 (Pubitemid 351159233)
20. AV Finn, M Joner, G Nakazawa et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization Circulation 115 2007 2435 2441 (Pubitemid 46717966)
21. J Mehilli, RA Byrne, A Wieczorek et al. Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis Eur Heart J 29 2008 1975 1982
22. RA Byrne, A Kastrati, S Kufner et al. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial Eur Heart J 30 2009 2441 2449
23. MI Hamilos, M Ostojic, B Beleslin et al. Differential effects of drug-eluting stents on local endothelium-dependent coronary vasomotion J Am Coll Cardiol 51 2008 2123 2129 (Pubitemid 351721001)
24. RA Byrne, A Kastrati, S Massberg et al. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease 3-year outcomes from a randomized clinical trial J Am Coll Cardiol 58 2011 1325 1331
25. RA Byrne, S Kufner, K Tiroch et al. Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results Heart 95 2009 1489 1494
26. J Daemen, P Wenaweser, K Tsuchida et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study Lancet 369 2007 667 678 (Pubitemid 46281313)
27. L Raber, L Wohlwend, M Wigger et al. Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the sirolimus-eluting versus paclitaxel-eluting stents for coronary revascularization LATE trial Circulation 123 2011 2819 2828
28. Cordis Cordis announces discontinuation of NEVO and CYPHER sirolimus - eluting coronary stents http://www.cordis.com/sites/default/files/pdfs/ CORDIS20ANNOUNCES20DISCONTINUATION20OF20NEVO.pdfzoom=100 (accessed Oct 19, 2011).
29. Johnson and Johnson Third-quarter and nine-month 2011 financial results http://www.jnj.com/wps/wcm/connect/JnJ.Com20Development/development/pdf/ earnings/q3+2011+news+release+charts.pdf (accessed Oct 19, 2011).
30. Cordis CYPHER sirolimus-eluting coronary stent http://www.cordis.com/ products/cypher-sirolimus-eluting-coronary-stent (accessed Oct 19, 2011).
31. PC Smits, E Kedhi, KJ Royaards et al. 2-year follow-up of a randomized controlled trial of everolimus- and paclitaxel-eluting stents for coronary revascularization in daily practice. COMPARE (Comparison of the everolimus eluting XIENCE-V stent with the paclitaxel eluting TAXUS LIBERTE stent in all-comers: a randomized open label trial) J Am Coll Cardiol 58 2011 11 18
32. GW Stone, A Rizvi, K Sudhir et al. Randomized comparison of everolimus- and paclitaxel-eluting stents. 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial J Am Coll Cardiol 58 2011 19 25
33. K Rasmussen, M Maeng, A Kaltoft et al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial Lancet 375 2010 1090 1099
34. DW Park, YH Kim, SC Yun et al. Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial J Am Coll Cardiol 56 2010 1187 1195
35. C Kaiser, S Galatius, P Erne et al. Drug-eluting versus bare-metal stents in large coronary arteries N Engl J Med 363 2010 2310 2319
36. Jensen L. SORT OUT 4: a prospective randomized trial of everolimus eluting stents and sirolimus-eluting stents in patients with coronary artery disease. Transcatheter Cardiovascular Therapeutics Meeting, Washington DC, USA; Sept 24, 2010.
37. KW Park, IH Chae, DS Lim et al. Everolimus-eluting versus sirolimuseluting stents in patients undergoing percutaneous coronary Intervention: the EXCELLENT randomized trial J Am Coll Cardiol 58 2011 1844 1854
38. A de Waha, A Dibra, RA Byrne et al. Everolimus-eluting versus sirolimus-eluting stents: a meta-analysis of randomized trials Circ Cardiovasc Interv 4 2011 371 377
39. U Baber, R Mehran, SK Sharma et al. Impact of the everolimus-eluting stent on stent thrombosis a meta-analysis of 13 randomized trials J Am Coll Cardiol 58 2011 1569 1577
40. S Silber, S Windecker, P Vranckx, PW Serruys Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial Lancet 377 2011 1241 1247